An extensive literature has validated the critical importance of a brief post–trial consolidation period for the incorporation of an experience into memory. Importantly, during this active consolidation state the memory formation is vulnerable to modification. While the subsequent stabilization of the memory makes it relatively resistant to modification, conditioned drug cues that re-activate the cue drug state association can initiate a re-consolidation process and during this re-consolidation the drug-cue association again becomes briefly unstable and sensitive to modification by post-trial treatments. Although most post-trial treatments shown to interact with memory consolidation processes have been used with instrumental learning protocols, this review is focused on recent findings that indicate that psycho-stimulant drug responses induced by apomorphine and morphine during the post-trial consolidation/re-consolidation state can become incorporated into the memory process. As a consequence, these post-trial drug treatment effects can be expressed in a subsequent non-drug test as behavioral responses comparable to the drug induced responses. In fact, apomorphine and morphine when administered post-trial can induce sensitization/conditioned effects that mirror the effects generated when these same drugs are administered in the presence of contextual cues. In addition, it has been shown that apomorphine given at stimulant/inhibitory dopaminergic dose levels post-trial during re-consolidation of a conditioned drug behavior can intensify/reverse the drug conditioning previously induced by apomorphine, morphine or haloperidol. The apparent efficacy of a post-trial drug state induced by a psycho-stimulant drug during consolidation/re-consolidation to become incorporated into contextual memory points up an alternative way, in addition to Pavlovian conditioning, by which psycho-stimulant drug effects can become embedded into an engram activated by contextual cues. These findings further suggest that drug treatments can be used to counter-condition the re-consolidated conditioned addictive drug response to substantially reduce the salience and motivational significance the conditioned association induced by the addictive drug.

大量的文献证实了短暂的审判后合并期对于将经验纳入记忆的至关重要性。重要的是，在此活动合并状态期间，内存结构易受修改。虽然记忆的后续稳定使其相对抗修饰，但重新激活提示药物状态关联的条件药物提示可以启动重新整合过程，在此重新整合过程中，药物提示关联再次变得短暂不稳定和敏感可以通过审判后处理进行修改。尽管大多数显示出与记忆整合过程相互作用的试验后治疗方法已与工具学习协议一起使用，这篇综述的重点是最近的发现，这些发现表明在审判后巩固/重新巩固状态期间，由阿扑吗啡和吗啡诱导的心理刺激药物反应可以纳入记忆过程。结果，这些试验后的药物治疗效果可以在随后的非药物测试中表示为与药物诱导的反应相当的行为反应。实际上，阿朴吗啡和吗啡在试验后给药时可引起敏化/调节作用，这反映了在上下文提示下给药相同药物时产生的作用。此外，已经显示在条件药物行为的再巩固期间在试验后以刺激/抑制性多巴胺能剂量水平给予的阿扑吗啡可以增强/逆转先前由阿扑吗啡，吗啡或氟哌啶醇诱导的药物调节。心理刺激药物在巩固/重新巩固期间诱发并整合到情境记忆中所引起的试验后药物状态的明显功效，除了巴甫洛夫式调理外，还提出了一种替代方法，通过这种方法心理刺激药物的作用可以变为嵌入到由上下文提示激活的字母中。